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Introduction
Chlamydiae are obligate intracellular organisms that cause a wide spectrum of human and animal disease, including conjunctivitis, pneumonia, and genital tract infections. C trachomatis and C pneumoniae are significant human pathogens; C psittaci is a less common cause of human disease.
The earliest descriptions of what is believed to have been trachoma are found in ancient Chinese and Egyptian manuscripts. In 1907, Halberstaedter and von Prowazek found what they assumed (correctly) to be the causal agent in trachoma when they noted intracytoplasmic vacuoles with numerous particles in Giemsa-stained epithelial cells. Subsequently, similar inclusions were described in specimens taken from the eyes of babies who had ophthalmia neonatorum, from their mothers' uteruses, and from men who had urethritis. From 1929 to 1930, outbreaks of an "atypical pneumonia" acquired from psittacine birds stimulated more research, which led to Bedson's description of the characteristic developmental life cycle of all Chlamydiales. His accurate description of "an obligate intracellular parasite with bacterial affinities" was not fully appreciated for several decades because these new agents initially were believed to be viruses.
Classification
Under the 2000 taxonomy, the order Chlamydiales was divided into four families: Chlamydiaceae, Parachlamydiaceae, Waddliaceae, and Simkaniaceae. The family Chlamydiaceae was divided further into two genera, Chlamydophila and Chlamydia, based on ribosomal sequence analysis that showed less than 95% homology between Chlamydia and Chlamydophila. Chlamydophila includes the species C pneumonia, C psittaci, and nonhuman pathogens; the family Chlamydia includes C trachomatis and nonhuman pathogens. (1) 
Structure and Developmental Cycle
Chlamydiae are obligate intracellular bacteria that have a unique biphasic developmental cycle alternating between an infectious "elementary body" (EB) form and a metabolically active "reticulocyte body" (RB) form ( Figure) . The EB is believed to be endocytosed into the host cell via a membrane-bound vacuole called an "inclusion." This vacuole avoids phagolysosomal fusion and, hence, detection by the human immune system. Within 8 to 18 hours after endocytosis, the EB undergoes primary differentiation to form RBs. Between 18 and 36 hours after endocytosis, RBs replicate by repeated cycles of binary fission. Between 36 and 72 hours after endocytosis, the RB undergoes secondary differentiation back to the EB, with subsequent cell lysis and release of new EBs to infect other cells. The indolent and subacute nature of chlamydial infection might be explained by its occult presence within the vacuoles and its long cell cycle. Common to both the EB and the RB forms of the organism is the major outer membrane protein (MOMP), considered to be integral to the infective nature of Chlamydia. This antigen and its antibody have been used extensively in the development of diagnostic tests for C trachomatis.
Chlamydia trachomatis Infection
C trachomatis is responsible for a wide range of clinical diseases, including neonatal conjunctivitis, trachoma, pneumonia in young infants, genital tract infection, and lymphogranuloma venereum (LGV). In addition, evidence suggests that chlamydial infection in pregnancy contributes to preterm birth.
C trachomatis has at least 18 serologic variants, of which serovars A through K are responsible for ocular infections and serovars L1, L2, and L3 for LGV. Trachoma usually is caused by serovars A through C, and genital and perinatal infections are caused by serovars B and D through K.
Neonatal Conjunctivitis
C trachomatis is the most frequently identified infectious cause of neonatal conjunctivitis; it is transmitted perinatally by infected mothers. The prevalence of Chlamydia infection among pregnant women may be as high as 18%, especially among pregnant adolescents. Infected mothers transmit Chlamydia to babies born vaginally 50% of the time; those born by caesarean section who have intact membranes also may be infected. Approximately 25% to 50% of perinatally infected infants develop conjunctivitis. Symptoms include conjunctival edema, hyperemia, and watery-to-mucopurulent discharge. The symptoms typically develop 5 to 14 days after birth and can last for longer than 2 weeks. A pseudomembrane may form and bloody discharge may be present if infection is prolonged. Routine topical prophylaxis with silver nitrate, erythromycin, or tetracycline given to all infants to prevent neonatal gonococcal conjunctivitis is ineffective against chlamydial conjunctivitis. When chlamydial conjunctivitis is diagnosed in an infant, the infant's mother and her sexual partner(s) must be tested. If treated, symptoms of chlamydial conjunctivitis resolve; untreated infections may result in corneal and conjunctival scarring.
Neonatal Pneumonia
Pneumonia due to C trachomatis generally presents as a subacute infection 2 to 19 weeks after birth. The incidence of neonatal pneumonia among infants born to infected women is believed to be between 5% and 30%. Patients generally are afebrile. Presenting signs and symptoms include tachypnea, staccato cough, crackles (rales), and rarely, wheezing. Preterm infants may have episodes of apnea. Such signs and symptoms may be preceded by rhinorrhea, congestion, or conjunctivitis.
Chest radiography reveals infiltrates and hyperinflation, but lobar consolidation and pleural effusions usually are not present. Laboratory testing may reveal peripheral eosinophilia and elevated serum immunoglobulins. A positive nasopharyngeal culture is considered diagnostic of infection. However, antibiotic treatment should be started presumptively on clinical grounds. If untreated, symptoms can last for months and include persistent hypoxemia. Diagnosis of chlamydial pneumonia in an infant necessitates treatment of the infant's mother and her sexual partner(s).
Genital Tract Infection
Lower genital tract infection with C trachomatis in prepubescent females generally is asymptomatic, although vaginitis sometimes occurs. Perinatally acquired vaginal and rectal infection may persist asymptomatically for up to 18 months after birth, beyond which the possibility of sexual abuse must be considered. (2) In postpubertal girls, chlamydial infection is sexually transmitted and presents as urethritis, cervicitis, endometritis, salpingitis, or perihepatitis. Most cases of urethritis in this age group are due to chlamydial infection; vaginitis is not a common manifestation. Approximately 40% of women whose chlamydial infection is untreated develop pelvic inflammatory disease; 20% of these women may become infertile.
Chlamydial infection is the sexually transmitted infection reported most commonly in the United States, with an increasing estimated prevalence of more than 2,800,000 women. The highest rates occur among adolescent females 14 to 24 years of age. (3) As newer, noninvasive testing (Table 1) has become more available, considerable interest has been expressed in establishing acceptable screening strategies in this population. Because most infected individuals are asymptomatic, the prevalence likely is underestimated. Approximately 5% to 15% of routinely screened women younger than 25 years of age are infected with C trachomatis. Recurrence rates of up to 30% have been reported within a few months of initial diagnosis.
Because of the increasing risk of chlamydial infection in young women, both the Centers for Disease Control and Prevention (CDC) and the United States Preventive Services Task Force recommend annual Chlamydia screening for all sexually active women younger than age 25 years and for all pregnant women in the first trimester of pregnancy. (3)(4) In addition, the CDC recommends that heterosexual partners of infected women be treated and that all women be retested for Chlamydia approximately 3 months after treatment.
Trachoma
Trachoma, the most common infectious cause of blindness worldwide, is a chronic follicular keratoconjunctivitis with corneal neovascularization resulting from untreated or chronic infection. Blindness occurs in up to 15% of those infected. The World Health Organization (WHO) estimates that 6 million people in the world are blind as a result of trachoma and that more than 150 million individuals are infected. Trachoma is highly prevalent in socioeconomically disadvantaged areas where there is crowding and an inadequate clean water supply for basic hygiene. Depending on socioeconomic conditions, the world-wide prevalence of trachoma ranges from 3% to 40% of the population. Trachoma rarely occurs in the United States.
Active infection occurs primarily in young children (Ͻ10 years) and generally causes a mild, self-limited conjunctivitis that frequently is asymptomatic. Chronic, or cicatricial, disease, with subsequent scarring and blindness, occurs primarily in adults. Transmission is by direct contact with secretions from the eyes, nose, or throat or by fomites. The diagnosis is made on clinical grounds. Because of the largely asymptomatic nature and high prevalence of this disease, the WHO recommends periodic community-wide distribution of antibiotics such as azithromycin or topical tetracycline in certain areas of high prevalence. The WHO and the Alliance for the Global Elimination of Blinding Trachoma are involved in a campaign to eradicate trachoma by the year 2020 by combining interventions such as surgery, antibiotics, facial cleanliness, and environmental improvement (SAFE). (5) Diagnostic Testing (Table 1) Culture is the gold standard for diagnosing C trachomatis and is approved by the United States Food and Drug Administration (FDA) for use at all collection sites. Standard collection sites include the endocervix, male and female urethra, nasopharynx, conjunctiva, vagina, and rectum. In all medicolegal cases, culture is the preferred method for confirming the diagnosis. Because Chlamydia sp are obligate intracellular organisms, specimens must contain epithelial cells. They should be obtained by using an aluminum-shafted Dacron ® -tipped swab and transported and processed under specific temperature guidelines. Wooden or calcium alginate swabs should not be used because they may inhibit growth of the organism. After 48 to 72 hours of incubation, infected cells develop characteristic intracytoplasmic inclusions that subsequently are stained with fluorescentinfectious diseases chlamydial infections labeled monoclonal antibody specific for the MOMP of C trachomatis.
Nucleic acid amplification tests (NAATs) amplify nucleic acid sequences specific for the organism of interest. Various commercial tests use different target nucleic acid sequences and amplification methods. Examples of NAATs include polymerase chain reaction, transcriptionmediated amplification, and strand-displacement amplification. NAATs do not require viable organisms and can detect the target of interest from as little as a single copy of DNA or RNA. For this reason, their sensitivity approaches 98%, which is significantly greater than that of culture. Specificity may be close to that of culture. The FDA has approved NAATs for use with endocervical and urethral swabs as well as urine specimens. The ease of using urine specimens, together with the high sensitivity of NAATs, has made these tests the preferred method for screening. NAATs are technically demanding, however, and results vary, depending on the method or laboratory used.
There is no well-established sensitive and specific serum antibody test for C trachomatis infection. Many nonculture tests available for the detection of Chlamydia have the advantage of being less expensive than culture or NAATs. A summary of the preferred and other options for testing based on the sites of clinical infection is listed in Table 2 .
Treatment (Table 3)
Treatment of conjunctivitis and of genital tract infection should be decided on the basis of a positive diagnostic test. Treatment of neonatal pneumonia often is started presumptively based on the clinical picture and radiographic findings suggestive of the diagnosis. Neonatal conjunctivitis due to C trachomatis is treated with oral erythromycin. Topical therapies are ineffective. Approximately 10% to 20% of infants treated for conjunctivitis require retreatment. Pneumonia due to C trachomatis may be treated with erythromycin or azithromycin. Of note, an association has been described between the use of erythromycin, especially in the first 2 weeks after birth, and an increased risk of pyloric stenosis. C trachomatis genital tract infection in adolescents and adults is treated with oral doxycycline or azithromycin. For children younger than 6 months of age, erythromycin is recommended.
Chlamydophila pneumoniae Infection
C pneumoniae causes an atypical pneumonia, with insidious or sudden onset of symptoms of mild-to-severe disease. Manifestations include cough, which may be prolonged from 2 to 6 weeks, and less frequently, sore throat and laryngitis. Extrapulmonary manifestations include nonexudative pharyngitis, bronchitis, acute otitis media, and sinusitis. Clinically, pneumonia due to C pneumoniae may be difficult to distinguish from other atypical (eg, Mycoplasma) or viral pneumonias. Transmission is presumed to be person-to-person by respiratory droplet, with an incubation period of approximately 21 days. No animal reservoirs are known. Chest radiography may show one or more areas of patchy infiltration; the white blood cell count generally is normal.
Pneumonia due to C pneumoniae is seen worldwide. In the United States, it is seen most commonly in children ages 5 to 15 years of age; in developing nations, it has a younger peak age of presentation. Diagnosis is made on clinical grounds, although there are no definitive diagnostic criteria. Patchy infiltrates on chest radiography may suggest the diagnosis. C pneumoniae is considered responsible for 6% to 22% of lower respiratory infections in children. In general, infection with C pneumonia is short-lived and does not confer persistent immunity.
Serologic testing, specifically microimmunofluorescence (MIF), is the only approved method of diagnosis and, therefore, is the reference standard for other diagnostic methods. Acute C pneumoniae infection is defined as a single immunoglobulin M (IgM) titer of at least 1:16 or a greater than fourfold increase in IgG titer by MIF. In primary infections, IgM antibodies do not appear until 2 to 3 weeks; IgG antibodies appear in 6 to 8 weeks. Therefore, MIF is not useful for making a prospective diagnosis. Despite being the "gold standard," MIF is an insensitive test, especially in children, compared with culture. Polymerase chain reaction, enzyme-linked immunosorbent assay, and direct fluorescent antibody testing are other available tools for diagnosis that have varying advantages and disadvantages, as with their use for detecting C trachomatis.
Treatment
Treatments include erythromycin (40 to 50 mg/kg per day divided QID), azithromycin (10 mg/kg per day on 
Chlamydophila psittaci Infection
C psittaci, the cause of psittacosis, may be transmitted by many birds such as parakeets, parrots, macaws, pigeons, and turkeys, which serve as its reservoir. People living or working closely in the environment of sick birds are especially at risk for acquiring the disease. Psittacosis occurs worldwide and may occur sporadically. This infection is relatively rare in children. The incubation period is 5 to 14 days or longer. In contrast to infection with C pneumoniae, psittacosis is characterized by the abrupt onset of fever, nonproductive cough, headache, and malaise. The radiographic finding of interstitial infiltrates may be worse than the clinical picture. Rare extrapulmonary complications include pericarditis, myocarditis, endocarditis, hepatitis, and encephalopathy. C psittaci infection is diagnosed by a fourfold increase in acute and convalescent serum antibody concentrations. The treatment of C psittaci infections is similar to that of C pneumoniae infections.
Areas for Additional Research
C pneumoniae has been proposed as a causative agent in asthma and atherosclerosis. This proposal makes intuitive sense because C pneumoniae is an intracellular organism that tends to lead to prolonged, often repeated infections. However, studies to date have yielded conflicting data about its protective role in asthma versus its causative role in the disease. The proposed association between this organism and atherosclerosis currently is being investigated prospectively.
Summary
Chlamydial infections are highly prevalent and affect all age groups. Most are indolent and subacute, potentially resulting in long-term morbidity, including chronic pelvic pain, infertility, and trachoma-related blindness. Several available diagnostic tests have varying degrees of sensitivity, specificity, and clinical utility. The NAAT tests have greatly improved the ability to conduct 
